319 related articles for article (PubMed ID: 8308273)
1. Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy.
Freedman RS; Tomasovic B; Templin S; Atkinson EN; Kudelka A; Edwards CL; Platsoucas CD
J Immunol Methods; 1994 Jan; 167(1-2):145-60. PubMed ID: 8308273
[TBL] [Abstract][Full Text] [Related]
2. Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial.
Freedman RS; Edwards CL; Kavanagh JJ; Kudelka AP; Katz RL; Carrasco CH; Atkinson EN; Scott W; Tomasovic B; Templin S
J Immunother Emphasis Tumor Immunol; 1994 Oct; 16(3):198-210. PubMed ID: 7834119
[TBL] [Abstract][Full Text] [Related]
3. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
[TBL] [Abstract][Full Text] [Related]
4. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
5. Transduction of rIL-2 expanded CD4+ and CD8+ ovarian TIL-derived T cell lines with the G1Na (neor) replication-deficient retroviral vector.
Nash MA; Platsoucas CD; Wong BY; Wong PM; Cottler-Fox M; Otto E; Freedman RS
Hum Gene Ther; 1995 Nov; 6(11):1379-89. PubMed ID: 8573611
[TBL] [Abstract][Full Text] [Related]
6. Characterization of tumor-infiltrating lymphocytes derived from human tumors for use as adoptive immunotherapy of cancer.
Schiltz PM; Beutel LD; Nayak SK; Dillman RO
J Immunother; 1997 Sep; 20(5):377-86. PubMed ID: 9336745
[TBL] [Abstract][Full Text] [Related]
7. Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites.
Ioannides CG; Platsoucas CD; Rashed S; Wharton JT; Edwards CL; Freedman RS
Cancer Res; 1991 Aug; 51(16):4257-65. PubMed ID: 1868446
[TBL] [Abstract][Full Text] [Related]
8. Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer.
Junker N; Andersen MH; Wenandy L; Dombernowsky SL; Kiss K; Sørensen CH; Therkildsen MH; Von Buchwald C; Andersen E; Straten PT; Svane IM
Cytotherapy; 2011 Aug; 13(7):822-34. PubMed ID: 21428850
[TBL] [Abstract][Full Text] [Related]
9. HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2.
Kooi S; Zhang HZ; Patenia R; Edwards CL; Platsoucas CD; Freedman RS
Cell Immunol; 1996 Dec; 174(2):116-28. PubMed ID: 8954611
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
Bouet-Toussaint F; Genetel N; Rioux-Leclercq N; Bansard JY; Levêque J; Guillé F; Patard JJ; Lesimple T; Catros-Quemener V
Eur Cytokine Netw; 2000 Jun; 11(2):217-24. PubMed ID: 10903800
[TBL] [Abstract][Full Text] [Related]
11. Study of tumor-infiltrating lymphocytes for adoptive therapy of renal cell carcinoma (RCC) and metastatic melanoma: sequential proliferation of cytotoxic natural killer and noncytotoxic T cells in RCC.
Hayakawa K; Salmeron MA; Parkinson DR; Markowitz AB; von Eschenbach AC; Legha SS; Balch CM; Ross MI; Augustus LB; Itoh K
J Immunother (1991); 1991 Oct; 10(5):313-25. PubMed ID: 1790139
[TBL] [Abstract][Full Text] [Related]
12. Characterization of human tumor-infiltrating lymphocytes expanded in hollow-fiber bioreactors for immunotherapy of cancer.
Malone CC; Schiltz PM; Mackintosh AD; Beutel LD; Heinemann FS; Dillman RO
Cancer Biother Radiopharm; 2001 Oct; 16(5):381-90. PubMed ID: 11776755
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for peritoneal ovarian carcinoma metastasis using ex vivo expanded tumor infiltrating lymphocytes.
Freedman RS; Platsoucas CD
Cancer Treat Res; 1996; 82():115-46. PubMed ID: 8849947
[TBL] [Abstract][Full Text] [Related]
14. In search of specific cytotoxic T lymphocytes infiltrating or accompanying human ovarian carcinoma.
Apiranthitou-Drogari M; Paganin C; Bernasconi S; Losa G; Maneo A; Colombo N; Mantovani A; Allavena P
Cancer Immunol Immunother; 1992; 35(4):289-95. PubMed ID: 1387344
[TBL] [Abstract][Full Text] [Related]
15. Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma.
Bukowski RM; Sharfman W; Murthy S; Rayman P; Tubbs R; Alexander J; Budd GT; Sergi JS; Bauer L; Gibson V
Cancer Res; 1991 Aug; 51(16):4199-205. PubMed ID: 1868441
[TBL] [Abstract][Full Text] [Related]
16. Lymphocytes infiltrating ovarian malignant ascites: modulation of IL-2-induced proliferation by IL-4 and of selective increase in CD8+ T cells by TNF-alpha.
Ioannides CG; Rashed S; Fisk B; Fan D; Itoh K; Freedman RS
Lymphokine Cytokine Res; 1991 Aug; 10(4):307-15. PubMed ID: 1932375
[TBL] [Abstract][Full Text] [Related]
17. Specific antitumor activity of tumor-infiltrating lymphocytes expanded first in a culture with both anti-CD3 monoclonal antibody and activated B cells and then in a culture with interleukin-2.
Tamada K; Harada M; Okamoto T; Takenoyama M; Ito O; Matsuzaki G; Nomoto K
Cancer Immunol Immunother; 1995 Dec; 41(6):339-47. PubMed ID: 8635191
[TBL] [Abstract][Full Text] [Related]
18. Characterization of fresh (uncultured) tumour-infiltrating lymphocytes (TIL) and TIL-derived T cell lines from patients with renal cell carcinoma.
Mitropoulos D; Kooi S; Rodriguez-Villanueva J; Platsoucas CD
Clin Exp Immunol; 1994 Aug; 97(2):321-7. PubMed ID: 8050183
[TBL] [Abstract][Full Text] [Related]
19. Recombinant interleukin-2-expanded tumor infiltrating lymphocytes from human renal cell cancer do not exhibit autologous tumor cell-specific cytotoxicity.
Nishimura T; Terashima Y; Hattori T; Satoh M; Kondo Y; Kimura G; Yoshida K; Akimoto M
Urol Int; 1991; 47 Suppl 1():83-5. PubMed ID: 1949387
[TBL] [Abstract][Full Text] [Related]
20. Large scale expansion of human tumor infiltrating lymphocytes with surface-modified stimulator cells for adoptive immunotherapy.
Chin Y; Janssens J; Smeyers E; Bleus J; Zhang J; Raus J
Anticancer Res; 1992; 12(3):733-6. PubMed ID: 1622131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
